CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $484,447 | -19.5% | 10,673 | -0.5% | 0.00% | +100.0% |
| Q2 2023 | $601,933 | +155.1% | 10,722 | +185.5% | 0.00% | -50.0% |
| Q1 2022 | $236,000 | -56.1% | 3,755 | -47.0% | 0.00% | -60.0% |
| Q4 2021 | $537,000 | -75.7% | 7,084 | -64.2% | 0.01% | -83.3% |
| Q3 2021 | $2,214,000 | -28.5% | 19,786 | +3.5% | 0.03% | -31.8% |
| Q2 2021 | $3,095,000 | +44.2% | 19,116 | +8.6% | 0.04% | +29.4% |
| Q1 2021 | $2,146,000 | +15.1% | 17,603 | +44.5% | 0.03% | +13.3% |
| Q4 2020 | $1,865,000 | +94.1% | 12,180 | +6.0% | 0.03% | +66.7% |
| Q3 2020 | $961,000 | +93.8% | 11,489 | +70.3% | 0.02% | +63.6% |
| Q2 2020 | $496,000 | – | 6,746 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |